Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Chugai Had Tough Start in Final Year of Midterm Plan: Chairman Nagayama
July 30, 2012
- Takeda Initiates PIII Trial for Anticancer Agent Motesanib in Asia
July 27, 2012
- Serum Ca Levels Show No Increase in Coadministration of Forteo, Activated Vitamin D3: Eli Lilly Japan
July 27, 2012
- Keizai Doyukai Chairman Hasegawa Instructs Takeda to Create Countermeasures for Risk of Violence in Emerging Countries
July 27, 2012
- Tarceva Shows No Significant Difference in PIII Study, Indication for Hepatoma Difficult: Astellas
July 26, 2012
- Kyowa Hakko Bio’s Subsidiary Completes Drug Substance Production Facility Conforming to Japan, US, Europe GMPs
July 26, 2012
- Takeda Receives Positive Opinion from CHMP on Adcetris
July 26, 2012
- Taiho Licenses Anti-Allergy Drug from Faes Farma in Japan
July 26, 2012
- Sandoz Launches Generic Claritin
July 26, 2012
- MTPC Launches Low-dose Anxiolytic Depas on July 24
July 26, 2012
- MSD Changes Name of Aroglycem to Diazoxide to Prevent Medication Errors
July 25, 2012
- MSD to File NDA for Odanacatib in Japan in First Half of 2013
July 25, 2012
- New Research Lab for Plasma Fractionation Business to Be Set Up in Kobe
July 25, 2012
- Nippon Kayaku to Increase Production of Carboplatin Due to Sandoz’s Shipment Suspension
July 25, 2012
- Meiji Seika Pharma Discontinues Development of Schizophrenia Treatment AM-831
July 24, 2012
- AnGes MG to Conduct Domestic PI/II Trials of Collategene for Lymphedema in Fall
July 24, 2012
- IBL-Japan Concludes Codevelopment Agreement with IBL International for Diagnostic for Alzheimer Disease
July 24, 2012
- Kyowa Kirin Revises Business Forecast Upward on Steady Sales of Nesp
July 24, 2012
- Confident of Posting Sales of 100 Billion Yen with 3 Focal Products Including Teribone: Asahi Kasei Pharma President Asano
July 24, 2012
- Combination Drug Containing JR-051 to Be Developed: JCR
July 23, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…